A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis
Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved. UDCA treatment has an uncertain impact on disease outcomes and has been reported in hig...
Main Authors: | Dennis D. Black, Cara Mack, Nanda Kerkar, Tamir Miloh, Shikha S. Sundaram, Ravinder Anand, Ashutosh Gupta, Estella Alonso, Ronen Arnon, Pinar Bulut, Saul Karpen, Chuan‐Hao Lin, Philip Rosenthal, Matthew Ryan, Robert H. Squires, Pamela Valentino, Sarah H. Elsea, Benjamin L. Shneider |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-11-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1421 |
Similar Items
Similar Items
-
Primary Sclerosing Cholangitis: A Clinical Update
by: Sridhar Sundaram, et al.
Published: (2019-09-01) -
Primary Sclerosing Cholangitis
by: A Stiehl, et al.
Published: (2000-01-01) -
Primary sclerosing cholangitis
by: Marina G Silveira, et al.
Published: (2008-01-01) -
Primary sclerosing cholangitis
by: Chapman Roger, et al.
Published: (2006-10-01) -
Primary sclerosing cholangitis
by: Lemmer, Eric Richard
Published: (2017)